Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device

Luthringer, R.; Djupesland, Per G.; Sheldrake, Colin D.; Flint, A. P. F.; Boeijinga, Peter H.; Danjou, Philippe; Demazieres, Agnès; Hewson, G.

doi:10.1211/jpp/61.09.0012

Cited by 13 publications

(34 citation statements)

References 28 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(6,7) The delivery was well tolerated and no adverse events were reported. As previously shown for a bidirectional liquid device, (3) this study shows that bidirectional nasal delivery of a powder offers larger and more reproducible initial deposition to the upper and middle target sites with ciliated nasal mucosa found predominantly beyond the nasal valve when compared directly to a traditional hand- …”

Section: Discussionmentioning

confidence: 89%

“…1b) and the bidirectional delivery procedure has recently been described in detail elsewhere. (6,7) In brief, the dry powder was filled into a standard #3 inhalation grade capsule. To operate, the piercing button on the side of the device is pressed.…”

Section: Opt-powder Devicementioning

confidence: 99%

“…(1) It was against this background that a powder formulation of sumatriptan was developed and tested in placebo-controlled clinical Phase I and II trials using a bidirectional powder device for the treatment of acute mild to moderate migraine. (6,7) This device has shown compelling results in these studies. Scintigraphic techniques have been used to assess nasal deposition and clearance of radiolabeled liquid or powder formulations delivered with a variety of devices.…”

Section: Introductionmentioning

confidence: 97%

See 2 more Smart Citations

Nasal Deposition and Clearance in Man: Comparison of a Bidirectional Powder Device and a Traditional Liquid Spray Pump

Djupesland

Skretting

2012

Journal of Aerosol Medicine and Pulmonary Drug Delivery

132

142

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Opt-powder Devicementioning

confidence: 99%

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Nasal Deposition and Clearance in Man: Comparison of a Bidirectional Powder Device and a Traditional Liquid Spray Pump

Djupesland

Skretting

2012

Journal of Aerosol Medicine and Pulmonary Drug Delivery

132

142

View full text Add to dashboard Cite

show abstract

“…Upon actuation, the soft palate rises, isolating the nasal cavity from the oropharynx, and a fine powder of sumatriptan is deposited across the entire nasal mucosa on one side and then passes through to the other nostril. Because of the improved deposition of the drug, a phase I study was able to demonstrate that more sumatriptan is absorbed across the nasal cavity than traditional nasal delivery methods [6]. A phase II study was designed to evaluate the efficacy and safety of a single dose of 10 or 20 mg of a powder formulation of sumatriptan delivered with the OptiNose device in comparison with placebo [7].…”

Section: Triptan Variationsmentioning

confidence: 99%

Update on future headache treatments

Nagy

Rapoport

2013

Neurol Sci

View full text Add to dashboard Cite

Headache disorders are common and heterogenous neurologic entities. The complexities of management are further encumbered by the relatively few effective choices for acute and preventive therapies available to the headache specialist to treat these diverse disorders. As advances have been made in uncovering headache pathophysiology, new therapies have surfaced and others are forthcoming. This article will highlight new lines of care in development. There are several novel delivery mechanisms of familiar medications which bypass the limitations of current delivery systems, including the sumatriptan iontophoretic patch Zecuity, the intranasal sumatriptan OptiNose system, the zolmitriptan Rapidfilm orally dissolvable film and the orally inhaled dihydroergotamine Levadex system. New lines of care based upon recently discovered therapeutic targets will also be discussed including calcitonin gene-related peptide (CGRP) receptor antagonists, serotonin receptor agonists, and sphenopalatine ganglion (SPG) intermittent stimulation. Finally, emerging targets for future therapeutics will be explored including transient receptor potential vanilloid (TRPV1) receptor modulators, nitric oxide (NO) antagonists, gap junction modulators, glutamate receptor antagonists, orexin receptor antagonists and prostanoid receptor antagonists. Therapies developing over the next several years will be welcome additions to the headache specialist's armamentarium.

show abstract

“…In a phase I study, OptiNose proved to have more extensive absorption across the nasal mucosa than the existing sumatriptan liquid nasal spray device on the market [13]. A phase II study was designed to evaluate the efficacy and safety of a single dose of 10 or 20 mg of a powder formulation of sumatriptan delivered with the OptiNose device in comparison with placebo, in 117 adults with a moderate to severe intensity migraine attack [14].…”

Section: Unique Nasal Powder Delivery System Of Sumatriptan (Optinose)mentioning

confidence: 99%

The therapeutic future in headache

Rapoport

2012

Neurol Sci

View full text Add to dashboard Cite

There are many categories and individual types of headache and most have a variety of treatment protocols, while a few are best treated by just one medication. This paper will concentrate on acute care medications for migraine and discuss some new and future acute care treatments. There is not much to discuss about prevention, except that onabotulinumtoxinA has been approved for prevention of chronic migraine. Cluster headache will also be discussed, as there are some future treatments for acute care and prevention being studied at present. For the acute care of migraine in the US, we have seven triptans by tablet plus other routes and one non steroidal anti-inflammatory medication approved by the FDA that is currently available (Cambia brand of buffered diclofenac potassium for oral solution). There are several other acute care medications in various stages of development and there are three new methods of administering a triptan and others under investigation. The optimal acute care therapy for migraine should be faster, easier to use and more efficient with fewer adverse events than what is currently available. What follows is a brief review of the status in development for five of the many new acute care medications being investigated: the CGRP antagonist tablet telcagepant, the sumatriptan iontophoretic patch Zelrix, sumatriptan powder for use in the OptiNose apparatus, dihydroergotamine for oral inhalation (Levadex), civamide nasal solution for prevention of episodic cluster headache (Civanex) and sphenopalatine ganglion stimulation for acute cluster attacks in chronic cluster headaches. Other future treatments that will not be discussed include transcranial magnetic stimulation, a 5-HT 1F agonist named alniditan, large conductance calcium-activated potassium channel openers, glial modulators or other medications and devices in early stages of development.

show abstract

Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device

Cited by 13 publications

References 28 publications

Nasal Deposition and Clearance in Man: Comparison of a Bidirectional Powder Device and a Traditional Liquid Spray Pump

Nasal Deposition and Clearance in Man: Comparison of a Bidirectional Powder Device and a Traditional Liquid Spray Pump

Update on future headache treatments

The therapeutic future in headache

Contact Info

Product

Resources

About